ArticleBMC gastroenterology2025
Prognostic factors and survival outcomes in colorectal cancer: insights from a Ghanaian cohort.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) incidence in Ghana has increased significantly in recent years. Despite medical advances, survival rates remain low, with challenges in CRC screening implementation contributing to late-stage diagnoses and poor outcomes.
methodsThis study updates CRC survival estimates and identifies key prognostic factors influencing outcomes in a Ghanaian cohort. We conducted a retrospective analysis of 281 CRC patients diagnosed between 2016 and 2022 at Komfo Anokye Teaching Hospital in Kumasi, Ghana. Data on patient demographics, tumour characteristics, and clinical variables were collected. Survival estimates were calculated using the Kaplan-Meier method, and the log-rank test was used to compare overall survival (OS). Multivariable Cox proportional hazards models identified independent prognostic factors.
resultsThe median patient age was 54 years (95% CI: 53-58), with 27.8% under 45 years. Tumours were located in the colon (42.0%) and rectum (41.6%), with adenocarcinomas comprising 89.0% of cases. Stage III and IV diagnoses accounted for 39.1% and 29.9% of cases, respectively. There were 38.8% deaths, with a median OS of 45 months (95% CI: 32.5-57.5) and a 5-year OS rate of 39.3% (95% CI: 28.7-49.9). Poor OS was independently associated with stage II [aHR = 13.50, (95% CI: 1.74-104.75)], stage IV [aHR = 10.41, (95% CI: 1.16-93.11)], smoking [aHR = 1.72, (95% CI: 1.06-2.81)], multiple comorbidities [aHR = 2.72, (95% CI: 1.15-6.46)], and treatment with herbal medicine [aHR = 1.58, (95% CI: 1.04-2.38)]. Working in the informal sector was linked to improved OS [aHR = 0.57, (95% CI: 0.36-0.89)].
conclusionsCRC survival rates in this cohort were low, with a substantial proportion of patients experiencing mortality within five years following diagnosis. The findings highlight the critical need for early detection and intervention, particularly in younger populations to improve survival outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.